Paragonix Technologies Inc.
2 Canal Park, Fifth Floor
Cambridge
Massachusetts
02141
United States
Tel: 1-617-817-7790
Website: http://paragonixtechnologies.com/
71 articles about Paragonix Technologies Inc.
-
New International Study Reports Extension of the Donor Lung Transplantation Window
3/12/2024
Paragonix Technologies, Inc. announces the landmark publication of the first clinical manuscript assessing the use of FDA-cleared advanced organ preservation technology to significantly extend ischemic times, a term referring to the sensitive window of time between organ recovery and transplantation.
-
Paragonix Advanced Organ Preservation Enables Mid-America Transplant to Place High-Risk Donor Livers
1/17/2024
Paragonix Technologies is proud to publicly announce the recurrent success of a new, innovative strategy recently developed to minimize the complexities and logistics of placing high-risk donor livers.
-
Paragonix Technologies Unveils Expansive Organ Procurement Network
11/28/2023
Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the launch of a comprehensive network of donor organ procurement, preservation, and transportation services.
-
Paragonix Announces World’s First-In-Human Use of BAROguard™ Donor Lung Preservation System by Leading Academic Medical Center
11/17/2023
Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, has successfully completed the world’s first-in-human case utilizing its newest donor lung preservation technology, the BAROguard™ Donor Lung Preservation System, which received FDA 510(k) clearance in August 2023.
-
Paragonix Technologies, Leader in Organ Transplantation, Opens New U.S. Headquarters
10/4/2023
Paragonix Technologies, a pioneer in organ transplant solutions, is excited to announce the opening of its new corporate headquarters in Waltham, Massachusetts, marking a significant milestone in its journey to advance organ transplant innovations.
-
Record-breaking Donor Heart Transplant Utilizing the Paragonix SherpaPak®
5/23/2023
Paragonix Technologies, Inc. announces a milestone achievement with Massachusetts General Hospital successfully accessing a donor heart over a total of 2,506 nautical miles away using the Paragonix SherpaPak® Cardiac Transport System.
-
Clinical Study of Over 1,000 Transplant Recipients Demonstrates Improved Clinical Outcomes in Heart Transplantation with the Paragonix SherpaPak
4/21/2023
Paragonix Technologies, Inc., a leading organ transplant company, announces that the latest clinical report of over 1,000 transplant patients studied in the GUARDIAN-Heart Registry was presented at the 2023 ISHLT Annual Meeting & Scientific Sessions.
-
Clinical Evidence Points to Paragonix SherpaPak as Potential Solution to Expand Donor Heart Pool
4/20/2023
Paragonix Technologies, Inc. has presented new groundbreaking data on the clinical impact of using Paragonix SherpaPak Cardiac Transport System to preserve donor hearts from extended criteria donors.
-
Paragonix LUNGguard™ System Shown to Reduce Hospital Readmission Rates in Lung Transplant Recipients
4/20/2023
Paragonix Technologies, Inc., the leading organ transplant company, presented impactful clinical data on the use of its Advanced Organ Preservation system, LUNGguard™, in a study presented at this year’s ISHLT Annual Meeting & Scientific Sessions.
-
Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners
3/7/2023
Paragonix Technologies, Inc., a leading organ transplant company, announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners.
-
Latest Clinical Evidence Points to Paragonix SherpaPak® as a Tool to Reduce Unpredictable, Severe Complications following Heart Transplantation
3/6/2023
Paragonix Technologies, Inc., a leading organ transplant company, announces new research from a multi-center study on transplant patient outcomes following heart transplant surgery.
-
Paragonix Announces First Pediatric Use of LUNGguard™ System in Groundbreaking “Time Shift” Lung Transplantation Case
2/8/2023
Paragonix Technologies, Inc., a leading organ preservation provider, announced today a pioneering lung transplantation case in which donor lungs procured overnight were preserved with the LUNGguard Donor Lung Preservation System, allowing for next day transplant surgery led by Prof. Dr. Laurens Ceulemans at UZ Leuven in Belgium.
-
Legacy of Life Hawaii Utilizes Paragonix LUNGguard and LIVERguard for Donor Organs in First Transport from Hawaii to California
12/6/2022
Paragonix Technologies, Inc. achieves a historic milestone in Hawaii with the first-ever utilization of its advanced lung preservation technology, the Paragonix LUNGguard™ system, which protected, monitored and geo-tracked a pair of donor lungs throughout its lengthy voyage to California.
-
Clinical Evidence Shows Reduced Costs and Improved Outcomes in Heart Transplantation
11/22/2022
Paragonix Technologies, Inc., a leader in organ preservation technology and research, has announced the publication of a groundbreaking organ transplant study in the American Society for Artificial Internal Organs Journal.
-
Paragonix Launches Comprehensive Digital Platform for Real-Time Tracking of Donor Organs Destined for Transplantation
10/18/2022
Paragonix Technologies, Inc., a leader in Advanced Organ Preservation technology, has announced the launch of its new VantagePoint™ Organ Tracking Technology to pioneer a new era of continuous oversight and real-time visibility for donor organs in transit.
-
Paragonix Technologies Celebrates Clinical Milestone of over 2,000 Organs Preserved and Transported for Transplantation
8/17/2022
Paragonix Technologies, Inc. is announcing a major milestone of preserving over 2,000 donor organs, providing transplant centers Advanced Organ Preservation (AOPT) technology and a nationwide clinical support network.
-
Paragonix Expands Research for Advanced Organ Preservation Clinical Registries
7/19/2022
Paragonix Technologies , the leading hypothermic organ preservation provider, announced today its expanded enrollment in its GUARDIAN series of clinical registries aimed at investigating the impact of organ preservation.
-
Paragonix Technologies Announces Expanded Adoption of their LIVERguard™ System at the 2022 American Transplant Congress
6/7/2022
Paragonix Technologies, Inc., a leading organ preservation provider, announced expanded adoption of their LIVERguard Donor Liver Preservation System at the 2022 American Transplant Congress in Boston, Massachusetts.
-
Paragonix Technologies Presenting New Organ Preservation Research at the International Society of Heart and Lung Transplantation 2022 Annual Meeting
3/31/2022
Paragonix Technologies, Inc., a leading organ preservation provider, is presenting new research on a variety of organ preservation, transportation and clinical data collection topics.
-
Paragonix Technologies LUNGguard™ Used in Record Cross-Country Donor Lung Transplant Case
2/2/2022
Paragonix Technologies LUNGguard ™ Used in Record Cross-Country Donor Lung Transplant Case.